Article
Smoothened variants explain the majority of drug resistance in basal cell carcinoma.
Cancer cell - 9 Mar 2015
Atwood Scott X, Sarin Kavita Y, Whitson Ramon J, Li Jiang R, Kim Geurim, Rezaee Melika, Ally Mina S, Kim Jinah, Yao Catherine, Chang Anne Lynn S, Oro Anthony E, Tang Jean Y
Abstract excerpt
Advanced basal cell carcinomas (BCCs) frequently acquire resistance to Smoothened (SMO) inhibitors through unknown mechanisms. Here we identify SMO mutations in 50% (22 of 44) of resistant BCCs and show that these mutations maintain Hedgehog signaling in the presence of SMO inhibitors. Alterations include four ligand binding pocket mutations defining sites of inhibitor binding and four variants conferring...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.